Skip to main content
2024 AANS Annual Scientific Meeting Main banner
Back

Adam S. Arthur, MD, MPH (he/him/his)

Professor
UTHSC, Semmes-Murphey Clinic
Memphis, TN, US

Dr Arthur is the James T. Robertson Professor and Chair of the Department of Neurosurgery at the University of Tennessee Health Sciences Center and Semmes-Murphey Clinic. This is one of the largest and busiest neurosurgical practices in the country. His individual practice is focused on comprehensive treatment for patients with cerebrovascular disease. Dr Arthur has led several large multicenter clinical trials focused on new treatments for hemorrhagic and ischemic stroke patients and is commited to providing exceptional training for residents and fellows.

Disclosure(s): Arsenal Medical: Consultant (Ongoing); Azimuth: Stock Shareholder (excluding mutual funds) (Ongoing); Balt: Consultant (Ongoing), Grant/Research Support (Ongoing); Bendit: Stock Shareholder (excluding mutual funds) (Ongoing); Cerebrotech: Stock Shareholder (excluding mutual funds) (Ongoing); Cerenovus: Grant/Research Support (Ongoing); Endostream: Stock Shareholder (excluding mutual funds) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Magneto: Stock Shareholder (excluding mutual funds) (Ongoing); Medtronic: Consultant (Ongoing), Grant/Research Support (Ongoing); Mentice: Stock Shareholder (excluding mutual funds) (Ongoing); Microvention: Consultant (Ongoing), Grant/Research Support (Ongoing); Neuros Medical: Stock Shareholder (excluding mutual funds) (Ongoing); Penumbra: Consultant (Ongoing), Grant/Research Support (Ongoing); Perfuze: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); RevBio: Stock Shareholder (excluding mutual funds) (Ongoing); Scientia: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Serenity: Stock Shareholder (excluding mutual funds) (Ongoing); Siemens: Consultant (Ongoing), Grant/Research Support (Ongoing); Stryker: Consultant (Ongoing); Synchron: Stock Shareholder (excluding mutual funds) (Ongoing); Tulavi Therapeutics, Inc.: Stock Shareholder (excluding mutual funds) (Ongoing); Vastrax: Stock Shareholder (excluding mutual funds) (Ongoing); VizAi: Stock Shareholder (excluding mutual funds) (Ongoing)

Presentation(s):